Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2019 | Story Rulanzen Martin | Photo Johan Roux
Dionne
Dr Dionne van Reenen received her PhD during the December Graduation Ceremonies at the UFS

Very seldom in modern history do we try to critically think about how our bodies and even more those of women are presented in modern popular culture. Through her PhD research project, Dionne van Reenen attempts to critically analyse ideological formations of the body in performance and its discursive distribution in the consumption of contemporary popular media, adding to existing literature and research on the topic.

Her dissertation is titled Performing the Erotic: (Re)presenting the Body in Popular Culture.

Van Reenen, a senior researcher at the Unit for Institutional Change and Social Justice at the University of the Free State (UFS), received her PhD qualification specialising in English on Wednesday 11 December 2019 during the final ceremony of the December Graduation.

Van Reenen has extensive experience in all areas of education. Her work at the Unit for Institutional Change and Social Justice is interdisciplinary, involving both everyday and institutional politics. She also holds a Master’s degree in Philosophy, which she obtained in 2013 from the UFS. In 2016, she chaired the UFS Language Policy Review Committee and established the Gender and Sexual Equity Office, which formulated the Sexual Harassment, Misconduct, and Violence Policy at the UFS. 

Changing of social constructs in media consumption

“My study focuses on performative framings of social constructs of gender, race, and class (along with size, age, and ability) in the ordering processes of society,” she says.  These performative framings in are in turn sustained by the (re)presentation of eroticised bodies in popular visual media in the 21st century. “These framings and orderings are critiqued as nothing new, but simply entertainment product that is trading in ideologies and stereotypes that have long been in sociocultural circulation, and they affect how people think, speak and act.” 

The study also shows that the dynamics of ‘virtuality’ and ‘visuality’ in the digital age are altering traditional demarcations of space, place, time, and community, and have paved the way for formations of global cultures that are, at the same time, informative, expedient, empowering, homogenising, prescriptive, and imperialising.

Whilst the #MeToo movement focused more on gender-based violence, gender inequality, and sexual violence, which are big social issues and do not exist in isolation, Van Reenen used her critical philosophical training to understand how, in the current era, the dominant discourse on representations of the body, particularly marginalised bodies, has been constructed at the popular level. 

With every PhD research dissertation the candidate’s main aim is to add new knowledge to a discipline. For Van Reenen, it is important that her research can contribute to a change in social and cultural constructs by re-imagining the (re)presentations of the body in popular media.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept